15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering ProKidney Corp, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $12.00 to $12.00, so the covering firms are broadly aligned. The average target of $12.00 sits 503% above the current $1.99. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.59 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to ProKidney Corp.
As of Sep, 1 of 1 firms rate PROK a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PROK EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.19 – $-0.11 · 5 analysts · -1% YoY
Next period, 5 analysts expect ProKidney Corp. to earn $-0.14 a share (range $-0.19 – $-0.11), versus $-0.14 a year earlier. Full-year consensus is $-0.56, growing to $-0.59 the year after.
REVENUE · NEXT QUARTER
$453.4K
Range $73.0K – $1.6M · 5 analysts · +102% YoY
Revenue is expected to reach $453.4K (range $73.0K – $1.6M), +101.5% year-over-year. Full-year consensus is $507.1K, rising to $494.2K next year.
Top analysts covering ProKidney Corp.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PROK.
#1
Anupam Rama
JP Morgan · Rank #75
Hold
No targeton PROK
Overall win rate
51%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #125
Sell
$1.00-49.7% to target
Overall win rate
46%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$10.00+402.5% to target
Overall win rate
41%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Buy
$12.00+503.0% to target
Overall win rate
34%
+ Follow
#5
Vamil Divan
Guggenheim
Buy
$7.00+251.8% to target
Coverage
—
+ Follow
PROK stock forecast FAQ
What is PROK's average 12-month price target?+
The 1 analysts with a live target average $12.00 for ProKidney Corp. over the next 12 months, ranging from a $12.00 high to a $12.00 low.
Is PROK stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover PROK?+
1 analysts have an active rating on ProKidney Corp., and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering PROK?+
Among analysts who currently cover PROK, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #75). Their current call is Hold.
What is ProKidney Corp.'s projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.19 – $-0.11) across 5 analysts. Full-year EPS is projected at $-0.56, rising to $-0.59 the following year.
How much revenue is ProKidney Corp. expected to report next quarter?+
Consensus revenue is $453.4K (range $73.0K – $1.6M). Full-year revenue is projected at $507.1K, growing to $494.2K next year.
Have analysts been upgrading or downgrading PROK lately?+
As of Sep, 1 of 1 firms rate PROK a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PROK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
